FY2026 Earnings Forecast for GLSI Issued By Noble Financial

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Equities research analysts at Noble Financial issued their FY2026 earnings per share (EPS) estimates for Greenwich LifeSciences in a research note issued to investors on Wednesday, November 18th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($1.49) per share for the year. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.48) per share. Noble Financial also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.14) EPS.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.06).

Several other equities analysts have also weighed in on GLSI. HC Wainwright raised their price objective on shares of Greenwich LifeSciences from $69.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings raised shares of Greenwich LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $70.00.

View Our Latest Stock Analysis on GLSI

Greenwich LifeSciences Trading Down 1.6%

GLSI stock opened at $19.48 on Friday. The firm has a 50-day moving average of $16.87 and a two-hundred day moving average of $20.77. The firm has a market capitalization of $285.95 million, a PE ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GLSI. Ancora Advisors LLC raised its holdings in shares of Greenwich LifeSciences by 101.2% in the third quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock valued at $390,000 after buying an additional 10,870 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Greenwich LifeSciences by 44.4% during the third quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock worth $1,025,000 after buying an additional 17,464 shares during the period. BlackRock Inc. acquired a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $11,398,000. Deutsche Bank AG acquired a new stake in Greenwich LifeSciences in the second quarter valued at $126,000. Finally, Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $1,124,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Greenwich LifeSciences

Here are a few of the latest stories about GLSI:

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

Read More

Earnings History and Estimates for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.